Thermo Fisher Launches Gibco™ CTS™ DynaXS™ Single Use Bioreactor to Advance Scalable Cell Therapy Manufacturing

Thermo Fisher Scientific is a global medtech company, which has introduced the Gibco CTS DynaXS Single Use Bioreactor with the purpose to build expansion platform aiming to enable cell therapy developer for scaling manufacturer with flexibility, control, and regulatory readiness. 

With the increasing demand for cell therapies in commercialization, manufacturers face pressure to transition from static traditional culture systems to scalable and automation platform which helps to maintain consistent quality, financial control, and regulatory and cGMP compliance. Timelines in process operational flexibility with the demands of clinical manufacturing, with the development phase. 

According to Towards Healthcare, the cell and gene therapy for oncology market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 18.48 billion in 2026 to approximately USD 134.53 billion by 2035, representing a compound annual growth rate (CAGR) of 24.68% from 2026 to 2035. Growth is driven by the growing demand for personalized therapeutic approaches like cell and gene therapies, and with technological advancements and innovations in gene editing and personalized medicine are revolutionizing treatment options, leading to a more targeted approach to cancer treatment, making them a preferred choice for patients. 

Integrated Within the CTS Cell Therapy Ecosystem 

The CTS DynaXS bioreactor supports workflows from cell isolation and activation through expansion and downstream processing. This integration enables customers to build modular, scalable manufacturing strategies with unified technical support and regulatory documentation. 

The single-use bioreactor offers a broad operating range and flexible design, enabling customers to efficiently scale from small to large production across a wide variety of volumes, applications, and cell types. 

Senior Director of research and development at Thermo Fisher Scientific, Andy Campbell, said Manufacturers want platforms that grow with them, providing a solution designed specifically for cell expansion that aligns with the broader cell therapy manufacturing journey. 

About Thermo Fisher Scientific 

Thermo Fisher Scientific Inc. enables customers to make the world healthier, cleaner, and safer, reflecting its focus on innovation and scientific advancement. The company provides high-end analytical instruments, laboratory equipment, software, services, consumables, and chemicals to pharmaceutical/biotech companies, hospitals, research institutions, and government agencies. 

Customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, and improving patient health through diagnostics or the development and manufacture of life-changing therapies. It operates over 65 locations worldwide, serving academic, government, industrial, and healthcare clients. 

A recent report by Towards Healthcare highlights that the cell and gene therapy for oncology market is witnessing growth due to the high demand for manufacturing, logistics, and supply chain solutions to support personalized and complex treatments, and the shift toward precision medicine allows for tailored, patient-specific treatments. There are clinical trials in progress, indicating a strong, expanding pipeline of innovative candidates.